ArticleCPT: pharmacometrics & systems pharmacology2013
Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology.
Article in CPT: pharmacometrics & systems pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions.Journal of clinical pharmacology · 2026Review
- In silico models in oncology, neurology, and epidemiology: systems-level and multiscale perspectives.NPJ systems biology and applications · 2026Review
- Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.Scientific reports · 2022Article
- Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.The AAPS journal · 2021Article
- Patient-Specific Organoid and Organ-on-a-Chip: 3D Cell-Culture Meets 3D Printing and Numerical Simulation.Advanced biology · 2021Review
- Executable cancer models: successes and challenges.Nature reviews. Cancer · 2020Review
- Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.The Journal of pharmacology and experimental therapeutics · 2018Article
- Logic Modeling in Quantitative Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2017Article
- Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.Cancer research · 2017Article
- Clinical responses to ERK inhibition inNPJ systems biology and applications · 2017Article
- Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.CPT: pharmacometrics & systems pharmacology · 2016Article
- HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.PLoS computational biology · 2016Article
- Dual transcriptional-translational cascade permits cellular level tuneable expression control.Nucleic acids research · 2016Article
- Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.Journal of lipid research · 2016Article
- Physiome-on-a-Chip: The Challenge of "Scaling" in Design, Operation, and Translation of Microphysiological Systems.CPT: pharmacometrics & systems pharmacology · 2015Article
- Oxygen-Driven Tumour Growth Model: A Pathology-Relevant Mathematical Approach.PLoS computational biology · 2015Article
- Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.CPT: pharmacometrics & systems pharmacology · 2015Article
- Integrative analysis of cancer imaging readouts by networks.Molecular oncology · 2015Review
- Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Frontiers in pharmacology · 2015Article
- Implementation of quantitative and systems pharmacology in large pharma.CPT: pharmacometrics & systems pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
If mathematical modeling is to be used effectively in cancer drug development, future models must take into account both the mechanistic details of cellular signal transduction networks and the pharmacokinetics (PK) of drugs used to inhibit their oncogenic activity. In this perspective, we present an approach to building multiscale models that capture systems-level architectural features of oncogenic signaling networks, and describe how these models can be used to design combination therapies and identify predictive biomarkers in silico.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e71; doi:10.1038/psp.2013.38; published online 4 September 2013.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.